SVB Securities analyst Faisal Khurshid initiated coverage of Fusion Pharmaceuticals with an Outperform rating and $6 price target.
Published first on TheFly
SVB Securities analyst Faisal Khurshid initiated coverage of Fusion Pharmaceuticals with an Outperform rating and $6 price target.
Published first on TheFly